--- title: "CSPC Pharmaceutical Wins Shareholder Backing for All AGM Resolutions" type: "News" locale: "en" url: "https://longbridge.com/en/news/287964676.md" description: "CSPC Pharmaceutical Group's shareholders approved all resolutions at the AGM on May 28, 2026, including the 2025 audited financial statements and a final dividend of HK15 cents per share. The re-election of directors and the reappointment of Deloitte as auditor were also supported, despite some opposition. A special resolution to adopt new Articles of Association was passed, reflecting governance updates. The stock has a Buy rating with a target price of HK$13.05." datetime: "2026-05-28T15:11:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287964676.md) - [en](https://longbridge.com/en/news/287964676.md) - [zh-HK](https://longbridge.com/zh-HK/news/287964676.md) --- # CSPC Pharmaceutical Wins Shareholder Backing for All AGM Resolutions ### Memorial Day Sale – Claim 70% Off TipRanks - Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. - Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available. CSPC Pharmaceutical Group reported that shareholders at its annual general meeting on 28 May 2026 approved all ordinary resolutions, including receipt of the 2025 audited financial statements and a final dividend of HK15 cents per share. Investors also backed the re-election of executive and independent non-executive directors, the reappointment of Deloitte Touche Tohmatsu as auditor, share buyback and issuance mandates, and adoption of a new share option scheme, though some board and auditor items drew notable minority opposition. In addition, shareholders passed a special resolution to adopt new Articles of Association, signaling governance and structural updates aligned with the company’s evolving needs. The broad endorsement of management proposals, combined with refreshed incentive and capital management tools, reinforces the board’s authority and flexibility in steering future strategy, while the pockets of dissent highlight ongoing investor scrutiny over board composition and audit oversight. The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page. **More about CSPC Pharmaceutical Group** CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company listed on the Hong Kong Stock Exchange. It operates in the healthcare and drug manufacturing industry, focusing on the development, production and sale of pharmaceutical products for domestic and international markets. **Average Trading Volume:** 88,371,599 **Technical Sentiment Signal:** Hold **Current Market Cap:** HK$85.58B ### Related Stocks - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [562050.CN](https://longbridge.com/en/quote/562050.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) ## Related News & Research - [3D Medicines’ Envafolimab Trial in Biliary Tract Cancer to Headline 2026 ASCO Meeting](https://longbridge.com/en/news/287699826.md) - [Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial](https://longbridge.com/en/news/287276752.md) - [CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026](https://longbridge.com/en/news/284213122.md) - [CSPC Pharmaceutical Profit Slumps on Sharp Drop in Licence Fee Income](https://longbridge.com/en/news/287717554.md) - [CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate](https://longbridge.com/en/news/284559073.md)